Immune Pharmaceuticals Inc. (NASDAQ:IMNP) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 2,013,511 shares, an increase of 111.7% from the August 15th total of 951,173 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average daily volume of 2,642,330 shares, the days-to-cover ratio is presently 0.8 days.
Separately, FBR & Co restated a “buy” rating on shares of Immune Pharmaceuticals in a report on Wednesday, June 22nd.
Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 0.278 on Friday. Immune Pharmaceuticals has a 12-month low of $0.20 and a 12-month high of $1.57. The stock’s market capitalization is $22.01 million. The company has a 50-day moving average of $0.36 and a 200-day moving average of $0.40.
Immune Pharmaceuticals (NASDAQ:IMNP) last posted its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). Equities analysts expect that Immune Pharmaceuticals will post ($0.56) earnings per share for the current fiscal year.
In related news, Director Daniel Kazado bought 666,667 shares of the stock in a transaction that occurred on Thursday, August 4th. The stock was purchased at an average cost of $0.45 per share, for a total transaction of $300,000.15. Following the completion of the acquisition, the director now owns 907,290 shares in the company, valued at $408,280.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Gedeon Teper bought 937,500 shares of the stock in a transaction that occurred on Thursday, August 4th. The stock was bought at an average price of $0.38 per share, with a total value of $356,250.00. Following the completion of the acquisition, the chief executive officer now owns 5,748,405 shares of the company’s stock, valued at approximately $2,184,393.90. The disclosure for this purchase can be found here. 17.83% of the stock is currently owned by corporate insiders.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.